Published: 2021-11-24

Substance abuse, drug addiction and the role of primary health care amid the COVID-19 pandemic

Mustafa Elsaied Esmail, Majed Diaa Mosly, Abdulaziz Abdullah Alghamdi, Alalaa Hussain Hakami, Ahmed Ali Majrashi, Safwan Shaker Abdulrahim, Areej Mohammed Alnashry, Anwar Saeed Alalsaba, Baneen Abdullah Akakah, Khaled Abdullah Alshahrani, Nawaf Hatem Salamah


The definition of substance abuse is the use of certain types of drugs such as alcohol, cannabis, hash, cocaine and others that have serious side effects and clinical complications. There is a significant difference between substance abuse and the term addiction. The significant difference between substance abuse and addiction is that drug addiction or substance addiction is classified as a chronic disease controlling the physical and mental ability of the individual to unpleasant force to use specific drugs such as cocaine or else. The literature has a positive correlation between the COVID-19 pandemic and illegal drug abuse in substance abuse or addiction. COVID-19 caused emotional emptiness for many people around the world, in addition to anxiety and depression. The particular group of people started addicting to specific drugs to induce temporary happiness due to the unpleasant events they had from the pandemic. This article aimed to review the challenges of substance abuse and drug abuse in the COVID-19 pandemic and the role of public health in addition to primary care facilities against this phenomenon. To our knowledge, this is the first review providing a complex review about this issue since the beginning of COVID-19.


Substance abuse, Drug addiction, COVID-19, Primary care

Full Text:



Garofoli M. Adolescent substance abuse. Prim Care. 2020;47(2):383-94.

Camí J, Farré M. Drug addiction. N Engl J Med. 2003;349(10):975-86.

Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97(1147):312-20.

Sussman S, Skara S, Ames SL. Substance abuse among adolescents. Subst Use Misuse. 2008;43(12-13):1802-28.

Frances RJ. Substance abuse. JAMA. 1991;265(23):3171-2.

Dubey MJ, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S. COVID-19 and addiction. Diabetes Metab Syndr. 2020;14(5):817-23.

Erol A, Karpyak VM. Sex and gender-related differences in alcohol use and its consequences: contemporary knowledge and future research considerations. Drug Alcohol Depend. 2015;156:1-13.

Meckel KR, Kiraly DD. A potential role for the gut microbiome in substance use disorders. Psychopharmacology (Berl). 2019;236(5):1513-30.

Chick J. Alcohol and COVID-19. Alcohol Alcohol. 2020;55(4):341-2.

Delirrad M, Mohammadi AB. New methanol poisoning outbreaks in iran following COVID-19 pandemic. Alcohol Alcohol. 2020;55(4):347-48.

Mungmungpuntipantip R, Wiwanitkit V. Sharing alcoholic drinks and a COVID-19 outbreak. Alcohol Alcohol. 2020;55(4):343.

DeSousa A. Disulfiram ethanol reaction in a patient abstinent from alcohol caused by hand sanitizing. Alcohol Alcohol. 2020;55(4):349.

Szabo G, Saha B. Alcohol's effect on host defense. Alcohol Res. 2015;37(2):159-70.

Zyl-Smit RN, Richards G, Leone FT. Tobacco smoking and COVID-19 infection. Lancet Respir Med. 2020;8(7):664-5.

O'Donnell J, Gladden RM, Mattson CL, Hunter CT, Davis NL. Vital signs: characteristics of drug overdose deaths involving opioids and stimulants - 24 states and the district of Columbia, January-June 2019. MMWR Morb Mortal Wkly Rep. 2020;69(35):1189-97.

Wainwright JJ, Mikre M, Whitley P, Dawson E, Huskey A, Lukowiak A, et al. Analysis of drug test results before and after the US declaration of a national emergency concerning the COVID-19 outbreak. JAMA. 2020;324(16):1674-7.

Ochalek TA, Cumpston KL, Wills BK, Gal TS, Moeller FG. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. JAMA. 2020;324(16):1673-4.

Pastor F, Folgar MI, Carvalho N, Carvalho F, Horcajadas FA. Therapeutic cannabis and COVID-19: between opportunism and infoxication. Adicciones. 2020;32(3):167-72.

Laar MW, Oomen PE, Miltenburg CJA, Vercoulen E, Freeman TP, Hall WD. Cannabis and COVID-19: reasons for concern. Front Psychiatry. 2020;11:601653.

Khalsa JH, Bunt G, Maggirwar SB, Kottilil S. COVID-19 and cannabidiol (CBD). J Addict Med. 2021;15(5):355-6.

Tenegra JC, Leebold B. Substance abuse screening and treatment. primary care. Clinic Office Pract. 2016;43(2):217-27.